Qiagen scales its way up the IVD ladder through strategic acquisitions
This article was originally published in Clinica
Executive Summary
Diagnostics clearly is the market to invest in. The last few years have seen companies with a mainly research-oriented customer base buying in more clinically-relevant companies. Invitrogen, for example, acquired Applied Biosystems last year and now, as Life Technologies, has a prime position in the next-generation sequencing market, while Thermo Electron added a huge healthcare customer base with the Fisher acquisition of 2006 and, last month, bought biomarker expert BRAHMS. Of course, there are the players from the medtech field, such as Siemens Healthcare, which made three big diagnostics investments in DPC, Bayer’s diagnostics business and Dade-Behring. Even an established diagnostics company like Beckman Coulter continues to buy in new assets and expand its geographical reach, such as with the Olympus diagnostics unit.